Skip to content 
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. AbbVie Inc. has strategic partnership with OSE Immunotherapeutics. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. more
| Time Frame | ABBV | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -1.05% | 0.4% | -0.23% |
| 1-Month Return | 1.44% | -0.63% | -0.01% |
| 3-Month Return | 2.08% | 6.14% | 1.88% |
| 6-Month Return | 12.39% | 19.98% | 9.19% |
| 1-Year Return | 17.3% | 6.85% | 14.76% |
| 3-Year Return | 50.14% | 19.1% | 70.6% |
| 5-Year Return | 111.82% | 34.78% | 77.89% |
| 10-Year Return | 317.46% | 144.29% | 275.45% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 56.20B | 58.05B | 54.32B | 56.33B | 61.16B | [{"date":"2021-12-31","value":91.89,"profit":true},{"date":"2022-12-31","value":94.92,"profit":true},{"date":"2023-12-31","value":88.81,"profit":true},{"date":"2024-12-31","value":92.11,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Cost of Revenue | 17.45B | 17.41B | 20.41B | 16.90B | 9.96B | [{"date":"2021-12-31","value":85.46,"profit":true},{"date":"2022-12-31","value":85.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":82.8,"profit":true},{"date":"2025-12-31","value":48.81,"profit":true}] |
| Gross Profit | 38.75B | 40.64B | 33.90B | 39.43B | 51.20B | [{"date":"2021-12-31","value":75.69,"profit":true},{"date":"2022-12-31","value":79.38,"profit":true},{"date":"2023-12-31","value":66.22,"profit":true},{"date":"2024-12-31","value":77.02,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Margin | 68.96% | 70.00% | 62.42% | 69.99% | 83.71% | [{"date":"2021-12-31","value":82.38,"profit":true},{"date":"2022-12-31","value":83.63,"profit":true},{"date":"2023-12-31","value":74.56,"profit":true},{"date":"2024-12-31","value":83.62,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Expenses | 20.83B | 22.52B | 21.15B | 30.29B | 29.98B | [{"date":"2021-12-31","value":68.75,"profit":true},{"date":"2022-12-31","value":74.35,"profit":true},{"date":"2023-12-31","value":69.8,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":98.97,"profit":true}] |
| Operating Income | 17.92B | 18.12B | 12.76B | 9.14B | 21.21B | [{"date":"2021-12-31","value":84.49,"profit":true},{"date":"2022-12-31","value":85.4,"profit":true},{"date":"2023-12-31","value":60.13,"profit":true},{"date":"2024-12-31","value":43.07,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (7.32B) | (6.68B) | (8.19B) | (7.58B) | - | [{"date":"2021-12-31","value":-731900000000,"profit":false},{"date":"2022-12-31","value":-668400000000,"profit":false},{"date":"2023-12-31","value":-819100000000,"profit":false},{"date":"2024-12-31","value":-758100000000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | 12.99B | 13.48B | 6.25B | 3.72B | 6.60B | [{"date":"2021-12-31","value":96.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.38,"profit":true},{"date":"2024-12-31","value":27.57,"profit":true},{"date":"2025-12-31","value":48.95,"profit":true}] |
| Income Taxes | 1.44B | 1.63B | 1.38B | (570.00M) | 2.36B | [{"date":"2021-12-31","value":60.91,"profit":true},{"date":"2022-12-31","value":69.04,"profit":true},{"date":"2023-12-31","value":58.25,"profit":true},{"date":"2024-12-31","value":-24.11,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] |
| Income After Taxes | 11.55B | 11.85B | 4.87B | 4.29B | - | [{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true},{"date":"2024-12-31","value":36.18,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | 11.55B | 11.85B | 4.87B | 4.29B | - | [{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true},{"date":"2024-12-31","value":36.18,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 11.54B | 11.84B | 4.86B | 4.28B | 4.23B | [{"date":"2021-12-31","value":97.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.09,"profit":true},{"date":"2024-12-31","value":36.14,"profit":true},{"date":"2025-12-31","value":35.7,"profit":true}] |
| EPS (Diluted) | 12.68 | 13.87 | 11.11 | 10.12 | 10.00 | [{"date":"2021-12-31","value":91.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true},{"date":"2024-12-31","value":72.96,"profit":true},{"date":"2025-12-31","value":72.1,"profit":true}] |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| ABBV | |
|---|---|
| ROA (LTM) | 9.59% |
| ROE (LTM) | 11.07% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| ABBV | |
|---|---|
| Trailing PE | 94.27 |
| Forward PE | 15.72 |
| P/S (TTM) | 6.46 |
| P/B | 50.46 |
| EV/R | 7.49 |
| EV/Ebitda | 30.38 |
| PEG | 0.38 |
AbbVie Inc (ABBV) share price today is $223.945
Yes, Indians can buy shares of AbbVie Inc (ABBV) on Vested. To buy
Yes, you can purchase fractional shares of AbbVie Inc (ABBV) via the Vested app. You can start investing in AbbVie Inc (ABBV) with a minimum investment of $1.
You can invest in shares of AbbVie Inc (ABBV) via Vested in three simple steps:
The 52-week high price of AbbVie Inc (ABBV) is $241.12. The 52-week low price of AbbVie Inc (ABBV) is $159.05.
The price-to-earnings (P/E) ratio of AbbVie Inc (ABBV) is 94.2743
The price-to-book (P/B) ratio of AbbVie Inc (ABBV) is 50.46
The dividend yield of AbbVie Inc (ABBV) is 3.04%
The market capitalization of AbbVie Inc (ABBV) is $394.59B
The stock symbol (or ticker) of AbbVie Inc is ABBV
Consider the share price of AbbVie Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether AbbVie Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in AbbVie Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the AbbVie Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of AbbVie Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that AbbVie Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
